Skip to content

Monthly research recap

LSD research: October 2026

What October 2026's 7 new studies found, synthesized from the papers below. All LSD research →

The synthesis

Synthesized from 7 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for LSD, lysergic acid diethylamide, lysergide, then ranked by relevance.

Research indexed in October 2026 points toward LSD having measurable effects on mood and brain function: a meta-analysis of five RCTs found a moderate reduction in depressive symptoms, and a small trial in major depression found high-dose LSD increased working-memory-related brain activity. A drug-profile review reports a credible signal of rapid, durable anxiolytic activity after a single 100 µg dose in generalized anxiety disorder, though phase 3 results were not yet peer-reviewed. Evidence on safety is reassuring mainly in screened, supervised settings, and the empirical base remains small, with few trials, tiny samples, and unresolved questions about blinding and durability.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Efficacy, safety, and tolerability of lysergic acid diethylamide for the treatment of depressive symptoms: A meta-analysis and systematic review 2026 systematic review and meta-analysis 227 Supports Across five RCTs, LSD significantly reduced depression symptoms versus comparators (adjusted standardized mean difference −0.65, 95% CI −0.92 to −0.38), with acceptable all-cause discontinuation and three possibly related hospitalizations.
Psychedelics and psychosis: A systematic review of recent-era studies (1984-2025). 2026 systematic review Mixed Population surveys showed no consistent link between lifetime psychedelic use and psychosis and controlled trials showed minimal risk (one transient delusion case), while case reports showed higher psychiatric comorbidity and emergency data showed more psychotic symptoms.
Same Molecule, Different People: Selection, Substitution and Setting as Explanations for Divergent Perceptions of LSD Risk 2026 preprint (rapid computational evidence synthesis) Mixed Argues that clinical and street evidence on LSD safety diverge because they concern different people, substances, settings, and measures, noting that most LSD trials excluded psychosis or family history and that the evidence does not support a general safety claim.
Daily Briefing: Tiny doses of LSD seem to boost cognition 2026 news briefing Supports Reports that tiny doses of LSD improved the ability to focus, but only in women.
Investigating molecular and hemodynamic effects of LSD in the human brain. 2026 observational neuroimaging study with comparison cohort 7 Supports LSD occupied 5-HT2A receptors with high affinity, increased global cerebral and carotid blood flow, decreased global connectivity, and showed an anticlockwise hysteresis between plasma levels and subjective effects, distinguishing it from psilocybin.
LSD treatment affects working memory-related brain function in patients with major depressive disorder 2026 RCT (randomized, double-blind, parallel-group) 43 Supports High-dose LSD (100 and 200 µg) significantly increased working-memory-related brain responses versus low-dose (25 µg) in prefrontal, parietal, insular, striatal, and thalamic regions, correlating with task performance but not with treatment response.
DT120 (MM120): a single-dose orally disintegrating formulation of lysergide tartrate for generalized anxiety disorder 2026 review (drug profile) Supports Reports that a phase 2b dose-finding study of lysergide tartrate showed a credible signal of rapid and durable anxiolytic activity after a single 100 µg dose without mandated psychotherapy, while noting adoption depends on peer-reviewed phase 3 results, durability, retreatment data, and managing functional unblinding.

Points of agreement

  • LSD shows measurable therapeutic signal for depressive and anxiety symptoms across a meta-analysis, an RCT, and a drug-profile review.
  • Effects on brain function are demonstrable: receptor occupancy, blood-flow changes, altered connectivity, and increased working-memory-related activity.
  • Risk appears low in screened, supervised clinical settings, with serious events rare.
  • Authors consistently call for larger, better-controlled and peer-reviewed trials before clinical adoption.

Conflicts

  • Safety framing differs: trial and population data suggest minimal psychosis risk, while the preprint argues clinical evidence cannot support a general safety claim because high-risk individuals are excluded.
  • The depression RCT found brain-response changes that did not track mood improvement, leaving the mechanism linking neural and clinical effects unresolved.
  • One report describes cognitive benefit from tiny doses, whereas the drug-profile review stresses that 100 µg is a perceptible psychedelic dose and distinct from microdosing.

Gaps

  • Durability of symptom improvement and need for retreatment are not established.
  • Blinding integrity and functional unblinding are unresolved in psychedelic trials.
  • Samples are very small (7 and 43 participants in imaging studies; 227 across five trials).
  • Phase 3 results for the anxiety indication were not yet peer-reviewed.
  • Populations with personal or family psychiatric history are largely excluded from trials, limiting generalizability.
  • Dose-response and the role of psychological support remain unclear.
Browse these studies in the library